A kind of esterase phe14 and its coding gene and application

Abstract

The invention discloses esterase PHE14 as well as an encoding gene and an application thereof. A novel enzyme gene PHE14 is developed from (Pseudomonadaceae oryzihabitans) HUP022, the whole length is 645bp, and the esterase PHE14 encoded by using the gene contains 214 amino acids. By cloning the esterase gene PHE14 and connecting the gene with an expression vector pET-28a (+) and converting escherichia coli BL21 (DE3), after culture and inducible expression, the recombinant expressed esterase PHE14 can be obtained. The esterase PHE14 can be used for preparing chiral methyl lactate, the esterase PHE14 of recombinant expression is taken as a catalyst, and (S)-methyl lactate of which the optical purity is greater than 99% can be prepared. The esterase PHE14 has very high application values in fields such as biochemical engineering and biological medicines.

Description

technical field

[0001] The invention belongs to the fields of biochemical industry and biotechnology, and in particular relates to an esterase PHE14 and its coding gene and application. Background technique

[0002] Different enantiomers of chiral drugs often show completely different physiological activities and toxicity. For example, the R-type "reactin" is an analgesic and analgesic for pregnant women, while the S-type "reactin" is teratogenic to the fetus. Role; barbiturate S-(-) isomer has the effect of inhibiting nerve activity, while R-(+) isomer has excitatory effect. Therefore, the synthesis of chiral compounds in the pharmaceutical industry is of great significance. In order to reduce the enantiomers with toxic side effects and reduce their biological activity, the synthesis of optically pure chiral drugs has always been the focus of pharmaceutical research. In addition, due to the huge demand for chiral chemicals in the chemical industry, the synthesis of chiral...

Images